Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
EUR 163,72
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. In.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
EUR 163,72
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. In.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 180,48
Quantité disponible : 15 disponible(s)
Ajouter au panierEtat : New.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 181,41
Quantité disponible : 15 disponible(s)
Ajouter au panierEtat : New.
EUR 196,01
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 512.
Vendeur : preigu, Osnabrück, Allemagne
EUR 140
Quantité disponible : 5 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. Novel Developments in Stem Cell Mobilization | Focus on CXCR4 | Stefan Fruehauf (u. a.) | Taschenbuch | xiv | Englisch | 2014 | Humana | EAN 9781489993762 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
EUR 218,07
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 512.
Langue: anglais
Edité par Springer New York, Springer US, 2012
ISBN 10 : 146141959X ISBN 13 : 9781461419594
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
EUR 168,73
Quantité disponible : 1 disponible(s)
Ajouter au panierBuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.
Langue: anglais
Edité par Springer New York, Springer New York, 2014
ISBN 10 : 1489993762 ISBN 13 : 9781489993762
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
EUR 168,73
Quantité disponible : 1 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.
Vendeur : Revaluation Books, Exeter, Royaume-Uni
EUR 238,63
Quantité disponible : 2 disponible(s)
Ajouter au panierPaperback. Etat : Brand New. 512 pages. 9.26x6.11x1.03 inches. In Stock.
Vendeur : Revaluation Books, Exeter, Royaume-Uni
EUR 240,21
Quantité disponible : 2 disponible(s)
Ajouter au panierHardcover. Etat : Brand New. 1st edition. 496 pages. 9.25x6.25x1.00 inches. In Stock.
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
EUR 245,86
Quantité disponible : 1 disponible(s)
Ajouter au panierHardcover. Etat : Like New. Like New. book.
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
EUR 248,24
Quantité disponible : 1 disponible(s)
Ajouter au panierPaperback. Etat : Like New. Like New. book.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 279,88
Quantité disponible : 15 disponible(s)
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 282,33
Quantité disponible : 15 disponible(s)
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
EUR 126,26
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : new. Questo è un articolo print on demand.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
EUR 126,26
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : new. Questo è un articolo print on demand.
Langue: anglais
Edité par Springer New York Apr 2014, 2014
ISBN 10 : 1489993762 ISBN 13 : 9781489993762
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
EUR 160,49
Quantité disponible : 2 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented. 512 pp. Englisch.
Langue: anglais
Edité par Springer New York, Springer New York Feb 2012, 2012
ISBN 10 : 146141959X ISBN 13 : 9781461419594
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
EUR 160,49
Quantité disponible : 2 disponible(s)
Ajouter au panierBuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented. 512 pp. Englisch.
Vendeur : moluna, Greven, Allemagne
EUR 136,16
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. A concise review of the current status of knowledge and future developments of CXCR4 will be presented Contributors are internationally leaders in the field A comprehensive treatment of the subject with numerous color illustrationsR.
Vendeur : moluna, Greven, Allemagne
EUR 136,16
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. A concise review of the current status of knowledge and future developments of CXCR4 will be presented Contributors are internationally leaders in the field A comprehensive treatment of the subject with numerous color illustrationsR.
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 205,24
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. Print on Demand pp. 512 68 Illus. (35 Col.).
Vendeur : preigu, Osnabrück, Allemagne
EUR 141,20
Quantité disponible : 5 disponible(s)
Ajouter au panierBuch. Etat : Neu. Novel Developments in Stem Cell Mobilization | Focus on CXCR4 | Stefan Fruehauf (u. a.) | Buch | xiv | Englisch | 2012 | Humana | EAN 9781461419594 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
EUR 204,55
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. PRINT ON DEMAND pp. 512.
Langue: anglais
Edité par Springer New York, Springer Feb 2012, 2012
ISBN 10 : 146141959X ISBN 13 : 9781461419594
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
EUR 160,49
Quantité disponible : 1 disponible(s)
Ajouter au panierBuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 512 pp. Englisch.
Langue: anglais
Edité par Springer New York, Springer New York Apr 2014, 2014
ISBN 10 : 1489993762 ISBN 13 : 9781489993762
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
EUR 160,49
Quantité disponible : 1 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 512 pp. Englisch.
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 228,12
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. Print on Demand pp. 512 68 Illus. (35 Col.).
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
EUR 227,30
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. PRINT ON DEMAND pp. 512.